deltatrials

Small lymphocytic lymphoma Trials in Chicago, United States

Conditions / Small lymphocytic lymphoma / Chicago, United States

Small lymphocytic lymphoma is a medical condition with active clinical research programs worldwide.

25 total trials for this combination

Showing top 10 of 25 trials

Trials

NCT ID Title Status Phase
NCT02048813 Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma ACTIVE_NOT_RECRUITING
NCT03737981 Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING
NCT03737981 Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING
NCT04269902 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study RECRUITING
NCT03701282 Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING
NCT03737981 Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING
NCT03737981 Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING
NCT03701282 Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING
NCT03701282 Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING
NCT02048813 Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma ACTIVE_NOT_RECRUITING

Related Pages